May 18 (Reuters) – Merck said on Monday its experimental drug met the main goals of a late-stage trial in patients with a cancer of the uterus lining.
The company said its drug, sacituzumab tirumotecan, helped patients live longer and delayed the worsening of their disease compared with chemotherapy in those whose cancer had progressed despite receiving standard treatments.
The trial enrolled 776 patients with advanced or recurrent endometrial cancer.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Leroy Leo)
Brought to you by www.srnnews.com